The use of suppressive agents for the treatment of rheumatoid arthritis. 1993

P M Brooks
Medical Professorial Unit, St Vincent's Hospital, Sydney, Australia.

UI MeSH Term Description Entries
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000893 Anti-Inflammatory Agents Substances that reduce or suppress INFLAMMATION. Anti-Inflammatory Agent,Antiinflammatory Agent,Agents, Anti-Inflammatory,Agents, Antiinflammatory,Anti-Inflammatories,Antiinflammatories,Antiinflammatory Agents,Agent, Anti-Inflammatory,Agent, Antiinflammatory,Agents, Anti Inflammatory,Anti Inflammatories,Anti Inflammatory Agent,Anti Inflammatory Agents
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis

Related Publications

P M Brooks
March 1956, Bulletin on the rheumatic diseases,
P M Brooks
February 1960, Texas state journal of medicine,
P M Brooks
February 1996, Rheumatic diseases clinics of North America,
P M Brooks
July 2001, Managed care (Langhorne, Pa.),
P M Brooks
February 2007, Annals of the Academy of Medicine, Singapore,
P M Brooks
October 2008, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
P M Brooks
November 2000, Current pharmaceutical biotechnology,
Copied contents to your clipboard!